FDA to Review 3-Antigen Prophylactic Hepatitis B Vaccine
The vaccine candidate consists of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus.
The vaccine candidate consists of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus.
Study authors assessed whether convalescent plasma with high SARS-CoV-2 antibody titers would prevent progression to severe disease in older patients with COVID-19 if administered within 72 hours after the onset of mild symptoms.
A randomized controlled trial was conducted to evaluate the efficacy of umifenovir as a monotherapy for the hospitalized patients with COVID-19.
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
The goal of this study is to investigate the antimicrobial therapy, therapeutic response, and outcome of culture-negative PVO compared with culture-positive PVO.
World Health Organization expert provided data on 4 repurposed antiviral drugs – remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a – and its use in patients hospitalized with COVID-19.
Regeneron’s antibody cocktail for COVID-19, REGN-COV2, contains 2 neutralizing antibodies: casirivimab and imdevimab; results from the phase 1/2 trial reveal promising results for patients who were antibody-negative or had high viral loads.
The study authors describe the first use of valganciclovir treatment in lower-income countries for patients with CMVR, advanced HIV disease, and profound immunosuppression.
Researchers studied 61 HIV-infected individuals who switched from efavirenz- to integrase strand transfer inhibitor (INSTI)-based therapies.
Investigators reviewed patterns of antibiotic consumption in each of the WHO Access, Watch, and Reserve (AWaRe) categories over a span of 15 years and documented changes.